Angiopoietin and Adverse Outcomes in Cardiac Surgery
Angiopoietin Dysregulation to Predict Adverse Outcomes in Cardiac Surgery: the Prospective
Centre Hospitalier Universitaire, Amiens
200 participants
Mar 23, 2023
INTERVENTIONAL
Conditions
Summary
Cardiac surgery and cardiopulmonary bypass can lead to systemic organ failure trough excess inflammation and endothelial injury. The angiopoietin family represented by angiopoietin 1 and 2 can reflect endothelial injury by a decrease in angiopoietin 1 and an increase in angiopoietin 2. The investigators hypothesized that angiopoietin dysregulation could reflect organ failure related to cardiac surgery. The purpose of this project is to assess the association between angiopoietin dysregulation and adverse outcomes on cardiac surgery.
Eligibility
Inclusion Criteria1
- adult patient scheduled for cardiac surgery under cardiopulmonary bypass
Exclusion Criteria8
- patient less than 18 years old,
- redo surgery,
- urgent surgery,
- endocarditis,
- aortic root repair surgery
- aortic dissection
- heart beating surgery,
- heart transplantation
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
5 ml blood sample will be withdrawn at the surgery start and at the surgery end
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05817929